EPCAM and gastric adenocarcinoma: There are strong arguments to evaluate this treatment in patients with gastric carcinomatosis: [1] the poor prognosis of patients despite optimal treatment with a curative intent including HIPEC [2], the expression of the EpCAM antigen in nearly 90% of gastric adenocarcinoma [21], and [3] peritoneum is an immunocompetent organ, [4] peritoneal mesenchymal cells do not express the EpCAM antigen.